REDX.L Share Price (REDX)

Redmile are lending more money. But value of new loan is not disclosed so far: see registration of charge doc,at top of this page:

https://find-and-update.company-information.service.gov.uk/company/07368089/filing-history

For various reasons, I think we'll hear of some kind of corporate action from Redx soon (including perhaps them going for a US listing). I wouldn't be surprised if they say something next week.

Very interesting but we are locked in until something is announced 😕 hopefully hear something this year...?

I like the way Redx quietly get on with the job in hand and excellent news this morning with the FDA granting Fast Track designation to RXC008, Redx's pan-ROCK inhibitor. Worth noting this sentence:-

'Redx have been working closely with the FDA and the STAR consortium to define the regulatory pathway for this disease '

Well worth reading up on the STAR consortium, (Stenosis Therapy and Anti-Fibrotic Research consortium) a crohn's research group involving two top ranked crohn's institutions , the Cleveland and Mayo Clinics. In fact I think the Mayo Clinic is the top ranked hospital in the US for Crohn's. The consortium is headed up by Dr. Florian Rieder who is also one of Redx's expert advisers. Will be interesting to see whether the RXC008 clinical trial incorporates and of the biomarkers/imaging developments from the STAR consortium.

Looks like Redx's collaboration with the Garvan Institute is now producing some tangible benefit for Redx with the Australian Government funding clinical trials to test two drugs in pancreatic cancer, one of which is Redx's ROCK2 inhibitor, Zelasudil (RXC007):-

'Two new clinical trials led by the Garvan Institute of Medical Research will test whether targeting the dense, fibrous tissue surrounding pancreatic tumours could make one of Australia's deadliest cancers more vulnerable to treatment'

https://www.garvan.org.au/news-resources/news/new-clinical-trials-to-target-pancreatic-cancers-protective-shield